TY - JOUR
T1 - Advances in pancreatic cancer treatment
AU - Taghizadeh, Hossein
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/1/9
Y1 - 2025/1/9
N2 - Pancreatic cancer, one of the most challenging malignancies to treat, is characterized by poor survival rates. The identification of novel effective therapies, optimization of treatments for the elderly population, and elucidation of the role of chemoradiotherapy are critical issues. Recent studies presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting have demonstrated advancements in the treatment of this aggressive disease. This review summarizes three notable studies: the phase I trial of IBI389, the phase II GIANT trial, and the phase II/III GABARNANCE trial, each contributing new insights into therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC).
AB - Pancreatic cancer, one of the most challenging malignancies to treat, is characterized by poor survival rates. The identification of novel effective therapies, optimization of treatments for the elderly population, and elucidation of the role of chemoradiotherapy are critical issues. Recent studies presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting have demonstrated advancements in the treatment of this aggressive disease. This review summarizes three notable studies: the phase I trial of IBI389, the phase II GIANT trial, and the phase II/III GABARNANCE trial, each contributing new insights into therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC).
UR - http://www.scopus.com/inward/record.url?scp=85217243410&partnerID=8YFLogxK
U2 - 10.1007/s12254-024-01020-5
DO - 10.1007/s12254-024-01020-5
M3 - Journal article
SN - 1865-5041
VL - 18
SP - 22
EP - 25
JO - Memo - Magazine of European Medical Oncology
JF - Memo - Magazine of European Medical Oncology
IS - 1
ER -